Maze Therapeutics, Inc. (MAZE)

Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026

3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight

Maze Therapeutics, Inc. (NASDAQ:MAZE) Stock Has Consensus Price Target of $63.40

Maze Therapeutics (NASDAQ:MAZE) Shares Climb 4.5% – Still a Buy?

Maze Therapeutics (NASDAQ:MAZE) Shares Gap Up – Time to Buy?

Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000

Maze Therapeutics, Inc. (MAZE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Maze Therapeutics, Inc. $MAZE is Frazier Life Sciences Management L.P.’s 8th Largest Position

Maze Therapeutics to Participate in Three Upcoming Investor Conferences

BlackRock Inc. Purchases Shares of 3,502,841 Maze Therapeutics, Inc. $MAZE

Bank of America Corp DE Purchases 176,703 Shares of Maze Therapeutics, Inc. $MAZE

Maze Therapeutics: Intriguing Kidney Disease Assets Put This On The Watchlist

ARCH Venture Management LLC Makes New $122.98 Billion Investment in Maze Therapeutics, Inc. $MAZE

Maze Therapeutics Announces Appointments to Its Board of Directors

Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Can Maze Therapeutics, Inc. (MAZE) Climb 120.48% to Reach the Level Wall Street Analysts Expect?